Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib Neoadjuvant Therapy in Localized Prostate Cancer
NCT02643667Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jul 2016
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in prostate cancer (PCa), sponsored by Washington University School of Medicine. Started Jul 2016; status: completed.
02
Drugs
ibrutinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02643667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02643667.